Targeting FSP1 triggers ferroptosis in lung cancer - Nature The ferroptosis suppressor protein FSP1 has a critical role in ferroptosis protection of tumours across multiple in vivo models and is linked to worse prognosis in human lung adenocarcinoma, suggestin...

new out in Nature, targeting FSP1 to trigger ferroptosis
www.nature.com/articles/s41...
www.nature.com/articles/s41...

Lymph node environment drives FSP1 targetability in metastasizing melanoma - Nature Targeting FSP1 in lymph nodes has considerable potential for blocking melanoma progression.

Melanoma cells that spread to lymph nodes depend on FSP1 to survive, revealing a new metabolic vulnerability. New study in Nature by @mariopalma.bsky.social @ubellackerlab.bsky.social and colleagues shows that blocking FSP1 triggers ferroptosis and suppresses tumor growth in lymph node metastases.

Thanks Christian!!

Targeting FSP1 triggers ferroptosis in lung cancer - Nature The ferroptosis suppressor protein FSP1 has a critical role in ferroptosis protection of tumours across multiple in vivo models and is linked to worse prognosis in human lung adenocarcinoma, suggestin...

Be sure to also check-out complementary findings from the Pappagianokopolous Lab, also online today in Nature, targeting FSP1 in vivo in lung tumors! www.nature.com/articles/s41...

A huge thank you to all co-authors, especially Nathan Reticker-Flynn @retickerflynn.bsky.social Stanford) and Jess @ubellackerlab.bsky.social for her incredible mentorship and support.

Lymph node environment drives FSP1 targetability in metastasizing melanoma - Nature Targeting FSP1 in lymph nodes has considerable potential for blocking melanoma progression.

Excited to share my postdoctoral work, out today in Nature! www.nature.com/articles/s41...

We discovered that melanoma cells in lymph nodes gain a targetable FSP1 dependency that limits melanoma progression.

Join me in Boston October 6th for a 1-day conference on #mappingbiology to transform #cancertherapeutics. Register by September 25th to benefit from the complimentary (free) admission! Topics, speakers, and talk opportunities here: abcam.me/mappingbiolo...
@abcamofficial.bsky.social

Our team (hsph.harvard.edu/research/ube...) is excited to have contributed to the intranodal in vivo testing of the remarkable new compound, Fentomycin-1. Congrats to team Rodriguez et al. for the implications of this work in targeting ferroptosis in cancer. Check it out here!

Image of 3 researchers from Harvard Chan wearing white lab coats. Text overlay says 'Our research saves lives.' Harvard T.H. Chan School of Public Health shield and logo at the bottom.

For more than 100 years, Harvard Chan School has worked to build a world where everyone can thrive.

Our discoveries and solutions have improved life for millions of people around the globe. And we’re expanding that impact every day.

A reminder that for next month’s BCDI in place of our regular discussion, we encourage you to attend the Cutter Distinguished Lecture @met-hsph.bsky.social by the great Scott Dixon!

See you there: Monday May 12, 2025, Kresge Building at HSPH, G1 auditorium, 12:00-1:00pm

Short on time wrangling research hurdles or just life in general? @mariopalma.bsky.social and @mariesabatier.bsky.social have you covered with this focused spotlight on Ueda et al.’s work in Nature Cell Biology on oxidative niches and cancer cell dissemination. Spotlight article here: rb.gy/zi8wj9

🌟 Excited to share our latest spotlight! 🌟 Co-wrote with @mariopalma.bsky.social and Jessalyn @ubellackerlab.bsky.social, highlighting Ueda et al.'s study on oxidative niches driving immune evasion in tumors.

Check out our spotlight article here: rb.gy/zi8wj9
Ueda et al., 2025: rb.gy/674im7

Capivasertib Plus Abiraterone/ADT Improves rPFS in PTEN-Deficient mHSPC Capivasertib plus abiraterone and ADT improved rPFS in PTEN-deficient metastatic hormone-sensitive prostate cancer.

Great news for AKT inhibitors! Capivasertib in combo with abiraterone and ADT improves progression free survival in PTEN deficient prostate cancer! Anticipating approval for this combo, coming off the approval of capi in ER+be breast cancer. Good work AZ!

www.onclive.com/view/capivas...